LCLC-103H Cells

The LCLC-103H cell line is derived from a large cell lung carcinoma (LCLC), specifically established from the pleural effusion of an adult male patient with a diagnosis of large cell lung carcinoma with giant cells. The patient had previously undergone chemotherapy and radiotherapy. This cell line is particularly notable for its partial expression of neuroendocrine markers, which are typically associated with small cell lung cancer (SCLC) and certain neuroendocrine tumors. In particular, the antigen detected by the monoclonal antibody RNL-1 shows a focal surface expression in LCLC-103H cells, similar to that observed in some neuroendocrine carcinomas. However, the expression is not uniform across all cells, indicating heterogeneity within the cell population. LCLC-103H has been described in the literature as PAS (Periodic Acid-Schiff) negative, distinguishing it from other lung cancer subtypes. It also exhibits remarkable stroma formation, which is a significant characteristic of its histopathological profile. Moreover, this cell line is known to overexpress the proto-oncogene MYC, which plays a critical role in cell proliferation and tumorigenesis. Immunocytochemical studies have shown that LCLC-103H does not exhibit the full spectrum of neuroendocrine differentiation seen in SCLC, as it lacks reactivity with other neuroendocrine markers such as those identified by the antibodies RNL-2 and RNL-3. This distinction is crucial for differentiating LCLC from SCLC, which is more aggressive and typically exhibits a higher sensitivity to certain chemotherapeutic agents. The unique expression profile of LCLC-103H makes it a valuable model for studying the molecular and immunological characteristics of large cell lung carcinoma and its overlap with neuroendocrine features.